Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Aviso Wealth Management

Aviso Wealth Management lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 64.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,013 shares of the medical research company’s stock after buying an additional 1,185 shares during the period. Aviso Wealth Management’s holdings in Amgen were worth $941,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Grassi Investment Management acquired a new stake in shares of Amgen during the 1st quarter worth $2,283,000. Public Employees Retirement System of Ohio increased its holdings in shares of Amgen by 1.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 281,791 shares of the medical research company’s stock worth $81,161,000 after buying an additional 4,376 shares during the last quarter. Meyer Handelman Co. increased its holdings in shares of Amgen by 7.2% during the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after buying an additional 8,700 shares during the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of Amgen by 1.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock worth $1,388,000 after buying an additional 57 shares during the last quarter. Finally, Novak & Powell Financial Services Inc. acquired a new stake in Amgen in the 4th quarter valued at $803,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $322.67 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The company’s 50-day simple moving average is $328.77 and its 200-day simple moving average is $307.54. The stock has a market capitalization of $173.09 billion, a price-to-earnings ratio of 46.10, a PEG ratio of 2.98 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the prior year, the business earned $5.00 EPS. The business’s revenue was up 20.1% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.79%. Amgen’s dividend payout ratio is currently 128.57%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Bank of America increased their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 price target (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price target (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $325.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.